Cievert's solution, Penguin, is a digital platform that monitors patients remotely. It does so in order to automatically determine whether the patient is fine or whether they would benefit from follow-up. The solution has been developed in close partnership with clinicians (in multiple hospitals) and is used in NHS Trusts across the UK (including Cancer Centres).
The aim is to detect problems earlier, reduce unnecessary appointments, and improve the patient experience.
Penguin monitors patients by sending them PRO questions. Penguin then automatically analyses whether the patient’s answers are within tolerance. All results are available to clinicians in real-time, but if any result is out of tolerance then a clinician is automatically notified. This means that the clinician does not need to review data unless an alert is triggered, saving them time.
Penguin is also capable of pulling in data from hospital systems, medical devices, wearables, clinical tests (etc.) and automatically reviewing the readings.
Cievert’s solutions are highly scalable: all content is easily configurable to meet local requirements, depending on the hospital and the clinical area. Cievert does not dictate the questions nor the tolerance levels.
Cievert is well-established in the NHS; their solutions have managed over 150,000 oncology patients to date and currently manage 25% of the UK’s radiotherapy patients. They are working with hospitals outside the UK as well.
Cievert’s solutions are registered medical devices, comply with GDPR, and the company is ISO accredited (9001, 27001). Cievert have carried out an abundance of groundwork to ensure that Penguin meets the highest Information Governance standards and is capable of interfacing with existing hospital infrastructure. Cievert has thus been capable – for example – of launching Penguin in multiple NHS Trusts simultaneously within 2 weeks (as part of a national clinical trial that they are running with Sheffield University).
Penguin captures rich patient information in a structured way. Cievert is therefore working with Durham University to build a tool which anonymises data so that the value of the data is preserved without eroding anonymity.
Cievert are also working to apply machine learning to the data. The aims are to stratify risk more intelligently and detect adverse events earlier.
In sum: Penguin works in oncology + is cost-effective, innovative, beneficial to patients, easy and quick to implement, and scalable.
COO I head up Cievert's business development, including our internationalisation efforts